JAMA Network Home
Sign In
Editor's Pick Original Investigation

Pembrolizumab Plus Chemotherapy for Cervical Cancer

JAMA Oncology 10.1001/jamaoncol.2026.3547

September 10, 2026 at 11:00 AM EDT

Read the full article

In this exploratory analysis of the KEYNOTE-826 randomized clinical trial, the 5-year data confirm the durability of benefit and reinforce pembrolizumab plus chemotherapy (with or without bevacizumab) as a first-line standard-of-care option for recurrent and metastatic cervical cancer.

Corresponding Author: Kosei Hasegawa, MD, PhD, Department of Gynecologic Oncology, Saitama Medical University International Medical Center, 1397-1, Yamane, Hidaka, Saitama, Japan (koseih@saitama-med.ac.jp).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

https://jamanetwork.com/journals/jamaoncology/fullarticle/10.1001/jamaoncol.2026.3547?utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_term=091026

Copy to clipboard

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.

Editor's Picks